Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis

Abstract

Background: Cancer remains a leading cause of death globally, necessitating the identification of prognostic biomarkers to guide treatment decisions. The Royal Marsden Hospital (RMH) score, based on readily available blood tests and clinical features, has emerged as a prognostic tool, although its performance across variable clinical scenarios is not thoroughly delineated. Therefore, we aimed to systematically assess the association between RMH score and survival in cancer patients. Methods: We conducted a systematic literature search across Pubmed, Scopus, and Web of Science databases for studies published up to 15 February 2024. We performed a meta-analysis with the generic inverse variance method with a random-effects model and reported hazard ratios (HR) with 95% confidence intervals (CI). Results: Nineteen studies encompassing 127,230 patients were included. A higher RMH score was significantly associated with worse overall survival (OS) (HR: 2.09, 95% CI: 1.87–2.33, p < 0.001) and progression-free survival (PFS) (HR: 1.80, 95% CI: 1.48–2.18, p < 0.001). This association was consistent across various subgroups, including study population (clinical trial vs. real-world cohort), geographic region, and tumor type. Conclusion: This meta-analysis, including over a hundred thousand patients, demonstrates a negative association between a higher RMH score and survival in cancer patients. The RMH score holds promise as a readily available prognostic tool across diverse cancer types and clinical settings. Future research should focus on validating and refining this score to aid clinical decision-making.

Analysis of clinicopathological characteristics and prognosis on primary gastric adenosquamous carcinoma

“…Gastric adenocarcinoma has long been a subject of intense research interest, with the development of effective systemic treatments being a key area of investigation. Currently, chemotherapy, radiotherapy, surgery, and immunotherapy have reached a relatively mature stage of development, with prognostic indicators such as albumin, the number of metastatic lymph nodes, and immune-related adverse events having been extensively explored and playing a pivotal role in guiding clinical treatment 4 – 6 . Compared to typical gastric adenocarcinoma, GASC appears to exhibit more aggressive clinicopathological features and poorer prognosis.…”

A paradigm shift in diagnosis and treatment innovation for mucinous cystic neoplasms of the liver

“…Early detection, prompt treatment, and regular follow-up are vital for improved outcomes and prognosis. Identification of prognostic biomarkers is essential for guiding treatment decisions 14 .…”